Northway Biotech is an end-to-end contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of protein-based biologics and gene therapies. With continuous expansion, 20+ years of technical expertise and a vertically integrated service model, we are uniquely positioned to rapidly execute multiple projects across development stages, from preclinical to commercial, while ensuring full regulatory compliance.
Our 3 state-of-the-art facilities in the EU (Vilnius, Lithuania) and US (Waltham, MA) include comprehensive capabilities for cell line development, process development, analytical development, as well as cGMP manufacturing of drug substances and drug products. Whether mammalian cell culture or microbial processing is optimal for your product's development, our cGMP facilities are equipped with multiple production units to support the development and manufacturing of your drug substance and aseptic drug product.
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment
Read MoreMicreos Pharmaceuticals partners with Biologics CDMO Northway Biotech for its Engineered Endolysin therapeutic manufacturing program
Read MoreApril 23-24, 2025
San Diego, CA
Booth NA
June 16-19, 2025
Boston, MA
Booth TBA
September 23-26, 2025
Boston, MA
Booth TBA
September 17-18, 2025
Vilnius, Lithuania
Booth TBA
October 28-30, 2025
Frankfurt, Germany
Booth TBA
May 13-17, 2025
New Orleans, LA
Booth NA
October 7-12, 2025
Sevilla, Spain
Booth NA
